STOCK TITAN

Sensus Healthcare Q3 revenue falls 13%, loss widens

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Sensus Healthcare, Inc. (SRTS) reported third-quarter 2026 revenue of $5.995 million, down 13.0% from $6.884 million a year earlier. Unit shipments rose to 26 from 16, including eight carried over from the second quarter of 2026. The company attributed lower revenue mainly to a shift toward lower-priced SRT-100 systems, no sales to a historically large customer, and three systems shipped under Fair Deal Agreement and rental arrangements, compared with none a year earlier; revenue on these arrangements is recognized over the agreement term rather than at shipment.

Gross profit increased to $3.288 million from $2.713 million, and gross margin was 55% versus 39.1%. GAAP net loss was $1.493 million, compared with $0.943 million, while adjusted EBITDA loss narrowed to $1.468 million from $2.398 million. Sensus said it recently sold its 1,000th SRT system and is expanding physician education and patient awareness.

Cash, restricted cash and cash equivalents totaled $12.920 million as of September 30, 2026, versus $15.2 million on June 30, 2026; there were no borrowings under the revolving line of credit. For the first nine months, revenue was $11.679 million versus $22.543 million, and net loss was $12.868 million versus $4.552 million.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 4 points

How the balance works

Positive

  • Moderate pointGross profit rose 22.2% to $3.288 million in Q3 2026.
  • Moderate pointAdjusted EBITDA loss narrowed to $1.468 million from $2.398 million.
  • Moderate pointGross margin was 55%, compared with 39.1% a year earlier.

Negative

  • Moderate pointRevenue fell 13.0% to $5.995 million year over year.
  • Moderate pointGAAP net loss widened to $1.493 million from $0.943 million.
  • Moderate pointNine-month revenue fell to $11.679 million from $22.543 million.
  • Moderate pointNine-month net loss rose to $12.868 million from $4.552 million.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q3 revenue $5.995 million Three months ended September 30, 2026; $6.884 million in the same period of 2025.
Q3 gross profit $3.288 million Three months ended September 30, 2026; $2.713 million in the same period of 2025.
Q3 gross margin 55% Three months ended September 30, 2026; 39.1% in the same period of 2025.
Q3 net loss $1.493 million Three months ended September 30, 2026; $0.943 million in the same period of 2025.
Q3 adjusted EBITDA loss $1.468 million Three months ended September 30, 2026; $2.398 million in the same period of 2025.
Cash, restricted cash and cash equivalents $12.920 million As of September 30, 2026; $15.2 million as of June 30, 2026.
Nine-month revenue $11.679 million Nine months ended September 30, 2026; $22.543 million in the same period of 2025.
Nine-month net loss $12.868 million Nine months ended September 30, 2026; $4.552 million in the same period of 2025.
Adjusted EBITDA financial
"Adjusted EBITDA, a non-GAAP financial measure"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
non-GAAP financial measure financial
"Adjusted EBITDA, a non-GAAP financial measure"
A non-GAAP financial measure is a way companies present their financial results that excludes certain expenses or income to show how they believe their core business is performing. It matters because it can give a clearer picture of how the company is really doing, but it can also be used to make results look better than they actually are.
Fair Deal Agreement program financial
"under the Fair Deal Agreement program and rental arrangements"
reimbursement codes medical
"dedicated reimbursement codes now in effect"
Reimbursement codes are standardized identifiers used by insurance companies and government programs to classify medical services, procedures and drugs so providers can bill for payment. Think of them like barcodes or price tags that determine what a treatment is called and how much insurers will pay; getting the right code affects whether a product is paid for, how quickly it is adopted, and how much revenue a healthcare company can expect.
superficial radiotherapy medical
"superficial radiotherapy (SRT and IG-SRT) technology"
A local radiation treatment that uses low-energy X-rays to treat conditions confined to the skin surface, delivering concentrated energy only a few millimeters deep—like using a focused flashlight rather than a floodlight. Investors care because adoption, clinical guidelines, device sales, clinic capacity and insurance reimbursement for this noninvasive option directly affect revenue and growth prospects for medical-equipment makers and outpatient providers in dermatology and oncology.
deferred revenue financial
"Deferred revenue, current portion"
Cash a company has already received for goods or services it has promised but not yet delivered; it's recorded as a liability because the company still owes that product, service, or future revenue recognition. For investors, deferred revenue signals upcoming work or deliveries that will convert into reported sales over time and affects short-term obligations, cash flow quality, and how quickly a firm can grow recognized revenue—think of it like prepaid subscriptions or gift cards a business must honor later.
Revenue $5.995 million Down 13.0% year over year
Gross profit $3.288 million Up 22.2% year over year
Gross margin 55% Compared with 39.1% in Q3 2025
Net loss $1.493 million Compared with $0.943 million in Q3 2025
Adjusted EBITDA loss $1.468 million Compared with $2.398 million in Q3 2025

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue did SRTS report for Q3 2026?

SRTS reported $5.995 million in revenue for Q3 2026, down 13.0% from $6.884 million a year earlier. The company cited a shift toward lower-priced SRT-100 systems, no sales to a historically large customer, and revenue recognition over the agreement term for three systems under Fair Deal Agreement and rental arrangements.

What was SRTS’s net loss in Q3 2026?

SRTS reported a GAAP net loss of $1.493 million, compared with $0.943 million in Q3 2025. Its adjusted EBITDA loss was $1.468 million, compared with $2.398 million a year earlier.

What drove SRTS’s higher gross margin in Q3 2026?

Gross margin was 55%, compared with 39.1% in Q3 2025. Sensus attributed the increase in gross profit and margin primarily to product mix, including a higher proportion of shipments of higher-margin SRT-100 units compared with lower-margin SRT-100 Vision units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001494891 0001494891 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

 

SENSUS HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-37714

 

27-1647271

(State of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)
         

851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida

 

33487

(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (561) 922-5808

 

_________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  Trading Symbol(s)  Name of each exchange on which registered
Common Stock, par value $0.01 per share  SRTS  Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

SENSUS HEALTHCARE, INC.

 

FORM 8-K

CURRENT REPORT

 

Item 2.02Results of Operation and Financial Condition

 

On November 12, 2026, Sensus Healthcare, Inc. announced via press release its financial results for the third quarter of 2026. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

The press release makes reference to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures and other financial information is provided in the press release.

 

The information furnished under Item 2.02, including in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits

 

99.1       Press Release, dated November 12, 2026.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     SENSUS HEALTHCARE, INC.
        
Date: November 12, 2026  By: /s/ Javier Rampolla
       Javier Rampolla
       Chief Financial Officer

 

 

 

EXHIBIT INDEX

   
Exhibit
Number
Description
99.1 Press Release, dated November 12, 2026.

 

 

 

Exhibit 99.1

 

 

 

Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights

 

Commercial Momentum Builds with Broader Physician Engagement and Customer Adoption

 

New Dermatology Group Relationships Support Customer Expansion and Diversification Strategy

 

Increasing Patient Awareness and International Commercial Activities Create Additional Growth Opportunities

 

BOCA RATON, Fla., November 12, 2026 – Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026.

 

Highlights included:

●Revenues of $6.0 million compared with $6.9 million in the third quarter of 2025, reflecting a product mix of lower-priced SRT-100 systems and the absence of sales to a historically large customer.

●Gross profit increased to $3.3 million from $2.7 million in the third quarter of 2025 and gross margin improved to 55% from 39.1% in the prior-year period.

●Shipped 26 systems, including eight carried over from the second quarter of 2026 due to financing approval timing, compared with 16 in the prior-year period. Excluding those eight systems, 18 systems were shipped during the quarter, compared with six shipments to customers other than the Company’s historically largest customer in the third quarter of 2025.

●Continued physician education initiatives and expanded customer relationships, including initial system purchases by two large private equity-backed dermatology groups.

●Launched TreatSkinCancer.com, a consumer education resource designed to increase awareness of skin cancer treatment options, complementing the Company’s ongoing physician education initiatives.

●Advanced international market-development activities across Asia-Pacific, including Australia, New Zealand, China and Hong Kong.

●Subsequent to quarter end, placed the Company’s 1,000th SRT system, marking an important commercial milestone.

 

Management Commentary

 

"Our third quarter results reflect continued progress in building a broader, more diversified customer base and advancing our business toward sustainable profitability," said Joseph Sardano, Chairman and Chief Executive Officer. “With dedicated reimbursement codes now in effect, our conversations with physicians are increasingly focused on how to bring SRT into their practices.

 

“Our vision is to make SRT a more widely understood and accessible non-invasive treatment option for appropriate patients with non-melanoma skin cancer. We are expanding physician education and patient awareness, including through TreatSkinCancer.com, while pursuing opportunities internationally and developing additional revenue streams tied to system utilization, software and services. The recent sale of our 1,000th SRT system is a milestone I am particularly proud of.

 

 

 

“We have spent years advancing the technology and growing our installed base. Today, we have a reimbursement framework that we believe can support broader adoption and a more scalable business. Our focus is on converting these opportunities into sales, increasing utilization and building a more diversified, sustainably profitable business,” concluded Sardano.

 

Third Quarter 2026 Financial Results

 

Revenues were $6.0 million compared with $6.9 million for the quarter ended September 30, 2025, a decrease of $0.9 million, or 13.0%. The revenue decrease primarily reflected a shift in product mix toward lower-priced SRT-100 systems versus higher-priced SRT-100 Vision systems, resulting in a lower average selling price per unit, as well as the absence of sales to a historically large customer. In addition, three systems shipped during the quarter were under the Fair Deal Agreement program and rental arrangements compared to zero in the prior year period, for which revenue is recognized over the term of the agreement rather than at the time of shipment.

 

Unit shipments increased year-over-year to 26 systems, including eight carried over from the second quarter of 2026, compared with 16 systems in the prior-year period.

 

Cost of sales was $2.7 million compared to $4.2 million for the quarter ended September 30, 2025, a decrease of $1.5 million, or 35.7%. The decrease in cost of sales was primarily related to the product mix, including a higher proportion of SRT-100 units shipped compared to SRT-100 Vision units shipped, as SRT-100 units have a lower average cost per unit.

 

Gross profit was $3.3 million compared to $2.7 million for the three months ended September 30, 2025, an increase of $0.6 million, or 22.2%. Overall gross profit percentage was 55%, compared to 39.1% in the corresponding period in 2025. The increase in gross profit and margin was primarily driven by product mix, including a higher proportion of shipments of higher-margin SRT-100 units compared to lower-margin SRT-100 Vision units.

 

General and administrative expense was $2.3 million compared to $1.9 million for the quarter ended September 30, 2025, an increase of $0.4 million, or 21.1%. The net increase in general and administrative expense was primarily due to higher legal and professional fees offset by reduction of insurance cost.

 

Selling and marketing expense was $1.5 million, flat with the third quarter of 2025.

 

Research and development expense was $1.1 million compared to $1.8 million for the quarter ended September 30, 2025, a decrease of $0.7 million, or 38.9%. The decrease was primarily due to a reduction in lobbying cost and reduced headcount.

 

Other income of $0.1 million and $0.2 million for the quarters ended September 30, 2026 and 2025, respectively, relates primarily to interest income.

 

Net loss was $1.5 million, or $0.09 per share, compared with net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025.

 

Adjusted EBITDA was a negative $1.5 million, compared with negative $2.4 million for the third quarter of 2025. Adjusted EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided.

 

 

 

Cash, restricted cash and cash equivalents were $12.9 million as of September 30, 2026, compared with $15.2 million as of June 30, 2026. The Company had no outstanding borrowings under its revolving line of credit at September 30, 2026. Prepaid inventory was zero compared with $0.6 million as of June 30, 2026. Inventories were $18.0 million compared with $18.5 million as of June 30, 2026.

 

Conference Call and Webcast

 

Sensus Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss these financial results, provide a business update and answer questions.

 

Participants are encouraged to pre-register for the conference call using this link to receive a unique dial-in number to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). Please ask the operator to be connected to the Sensus Healthcare conference call.

 

The call will be webcast live and can be accessed at this link or in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

 

Use of Non-GAAP Financial Information

 

This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP). Sensus Healthcare management understands that investors and analysts use Adjusted EBITDA, a non-GAAP financial measure, in analyzing the Company’s performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

 

SENSUS HEALTHCARE, INC.

GAAP TO NON-GAAP RECONCILIATION

(unaudited)

 

   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
(in thousands)  2026   2025   2026   2025 
Net loss, as reported  $(1,493)  $(943)  $(12,868)  $(4,552)
Add:                    
Depreciation   81    98    263    283 
Stock compensation expense   70    73    209    219 
Income tax (benefit) expense   —    (1,466)   4,079    (2,079)
Interest income, net   (126)   (160)   (368)   (528)
Adjusted EBITDA, non-GAAP  $(1,468)  $(2,398)  $(8,685)  $(6,657)

 

 

 

About Sensus Healthcare

 

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

 

Forward-Looking Statements

 

This press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or “potential,” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this release as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable. Any forward-looking statements that we make in this release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this release is filed, except as may be required by applicable law.

 

Investor Relations Contact

Leigh Salvo

New Street Investor Relations

leigh@newstreetir.com

 

 

 

SENSUS HEALTHCARE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   For the Three Months Ended September 30,   For the Nine Months Ended September 30, 
(in thousands, except shares and per share data)  2026   2025   2026   2025 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
Revenues  $5,995   $6,884   $11,679   $22,543 
Cost of sales   2,707    4,171    6,632    12,573 
Gross profit   3,288    2,713    5,047    9,970 
Operating expenses:                    
General and administrative   2,253    1,917    6,079    6,111 
Selling and marketing   1,548    1,546    4,319    5,122 
Research and development   1,106    1,819    3,806    5,896 
Total operating expenses   4,907    5,282    14,204    17,129 
Loss from operations   (1,619)   (2,569)   (9,157)   (7,159)
Other income:                    
Interest income, net   126    160    368    528 
Other income, net   126    160    368    528 
Loss before income tax   (1,493)   (2,409)   (8,789)   (6,631)
Provision for (benefit from) income taxes   —    (1,466)   4,079    (2,079)
Net loss  $(1,493)  $(943)  $(12,868)  $(4,552)
Net loss per share – basic  $(0.09)  $(0.06)  $(0.78)  $(0.28)
diluted  $(0.09)  $(0.06)  $(0.78)  $(0.28)
Weighted average number of shares used in computing                    
net loss per share – basic   16,462,059    16,320,036    16,462,255    16,327,233 
diluted   16,462,059    16,320,036    16,462,255    16,327,233 

 

 

 

SENSUS HEALTHCARE, INC.

CONSOLIDATED BALANCE SHEETS

 

   As of September 30,   As of December 31, 
(in thousands, except shares and per share data)  2026   2025 
   (unaudited)     
Assets          
Current assets          
Cash, restricted cash, and cash equivalents  $12,920   $22,083 
Accounts receivable, net   1,403    6,041 
Inventories   17,965    14,563 
Prepaid inventory   —    1,522 
Notes receivable, current portion   609    — 
Other current assets   1,687    1683 
Total current assets   34,584    45,892 
Property and equipment, net   2,662    1,976 
Deferred tax asset   —    4,079 
Operating lease right-of-use assets, net   265    452 
Notes receivable, net of current portion   2,731    352 
Other noncurrent assets   309    288 
Total assets  $40,551   $53,039 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable and accrued expenses  $3,746   $3,343 
Product warranties   302    275 
Operating lease liabilities, current portion   278    262 
Deferred revenue, current portion   785    842 
Total current liabilities   5,111    4,722 
Operating lease liabilities, net of current portion   —    209 
Deferred revenue, net of current portion   —    10 
Total liabilities   5,111    4,941 
Commitments and contingencies          
Stockholders’ equity          
Preferred stock, 5,000,000 shares authorized and none issued and outstanding   —    — 
Common stock, $0.01 par value – 50,000,000 authorized; 17,055,095 issued and 16,462,059 outstanding at September 30, 2026; 17,056,845 issued and 16,463,809 outstanding at December 31, 2025   169    169 
Additional paid-in capital   46,300    46,090 
Treasury stock, 593,036 shares at cost, at September 30, 2026 and December 31, 2025   (3,876)   (3,876)
(Accumulated deficit) retained earnings   (7,153)   5,715 
Total stockholders’ equity   35,440    48,098 
Total liabilities and stockholders’ equity  $40,551   $53,039 

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading